This is a preview of subscription content, log in via an institution to check access.
Literatur
Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robiatti SF, Frontini L, Sacco C, Castiglioni F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli VR, Gebbia V (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372
Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Renschler MF (2013) Safety and efficacy of weekly nab®- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 24:314–321
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtmann SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457–3465
Rights and permissions
About this article
Cite this article
DURATION-Studie. Forum 32, 435–436 (2017). https://doi.org/10.1007/s12312-017-0329-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12312-017-0329-4